Wednesday 9 June
DAILY NEWS DAILY NEWS
iaspvirtualcongress.evareg.com
Schedule At-A-Glance
*All times are EST.
Virtual Congress How-To’s
10:00–10:10
President’s Welcome
LOGGING IN
10:10–10:20
Past President’s Remarks
10:20–10:30
Scientific Program Committee Chair Remarks
10:30–11:00
ain Prevention and Management P Must Begin In Childhood: The Key Role Of Psychological Interventions
• Go to the website and click Login in the top right hand corner of the page • Use your IASP credentials to login to the event
11:00–12:15
• Inferring Pain Intensity From Brain Signals: The Promise and the Challenges
• Neuropathic Pain Mind-Changers—Breaking News from Basic and Clinical Science • The Dynamic Role of the Amygdala in Pain Perception and Learning • Engaging the Patient Voice in Pain Research: Partnering with Patients to Achieve Research Relevance and Impact 12:15–13:30
Virtual Exhibits & Poster Viewing
13:30–14:45
• An Optimist’s View of Meta-Analysis and Systematic Review Methodology in Pain Research: Seeing the Opportunity in Every Difficulty
• Pain in a Dish: Using In Vitro Models to Investigate Pain Genetics, Ion Channel Trafficking and Disease Pathophysiology • Towards Understanding and Altering Disparities in Pain Care • Patient Stratification Methods for Neuropathic Pain Research 14:45–15:15
ohn D. Loeser Award Lecture: The Greatest J Teacher, Failure Is: Falsely Positive, Falsely Negative, and Falsely Interpreted Clinical Trials of Pain Treatments
15:15–16:00
V irtual Exhibits & Poster Viewing
See complete schedule details here.
UPDATE YOUR PROFILE • Click View Profile at the top of the page • Update your contact information • Select Specialty and Occupation if blank • Select Time Zone to set session start times to your location • Share My Profile to make your contact information available to other attendees • Click Save Profile at the bottom of the page VIEW THE UPCOMING SCHEDULE • Print your schedule by Downloading Schedule at a Glance at the top of the right hand corner of the page. VIEW A SESSION • Select the session you would like to attend from the drop down menu • Click Join a Session • Attendees can ask questions to the speakers and chat with other attendees VIEW A POSTER • Select Posters from the top navigation bar • Posters are searchable by Title, Author, and Topic • Click on the selected poster to view the abstract, hear the audio/video file and learn more VIEW AN EXHIBITOR • Select Exhibitors and Supporters from the top navigation bar to view all exhibitors • Attendees can visit exhibitor booths, chat with staff, and learn more about the organization and its offerings
#IASP2021 • #IASPWorldCongress • #IASPVirtualEducation
Wednesday 9 June
Wednesday 9 June
DAILY NEWS DAILY NEWS
iaspvirtualcongress.evareg.com
Welcome from Andrew Rice, Scientific Program Committee Chair Hello and welcome to IASP’s Virtual World Congress on Pain. This is a significantly different format than we anticipated in Amsterdam last summer. It has been my great privilege to serve as chair of the scientific program committee for the 18th Congress. I thank the speakers and their willingness to adapt their talks to these technologies; demonstrating an amazing flexibility. I believe we are delivering have be an exciting program containing most of the elements you would expect to see at an in-person Congress. This virtual Congress includes 15 plenary lectures, 40 topical workshops as well as poster abstracts highlighting the latest research, which cover the wide spectrum of IASP member interests. I sincerely thank the members of the scientific program committee who have freely provided support, hard work and time to a wonderful program. They are all volunteers. The work of SPC for Congress to provide an attractive and balanced program is difficult under the best of circumstances. For this Congress, they have not only served far longer than originally asked, they have also willingly gone the extra mile when it came to adapting the program to a virtual format. The timetable for converting to a global virtual event has been challenging. Unfortunately, there is no ideal timing solution for everyone. We have scheduled two days of this six day virtual Congress to respect the needs of the 25% of IASP members who reside in Asia or Australasia. Furthermore, we recognize that many of our members have had to prioritize their time to clinical duties during the current COVID-19 pandemic. Therefore, all sessions are being recorded and will be available on-demand to be viewed at your convenience if you cannot make the live screenings.
10:30–11:00 EST
14:45-15:15 EST
An Interview With Robert Dworkin
Pain Prevention and Management Must Begin In Childhood: The Key Role Of Psychological Interventions
John D. Loeser Distinguished Award Lecture
By Kate Sukal
TONYA PALERMO PhD, University of Washington School of Medicine, United States Audience: Cross disciplinary | Topic: Clinical psychology Pain conditions in childhood often continue into adulthood. Childhood chronic pain is related to emotional, health behavior, social/family, and neurobiological vulnerabilities that contribute to the onset of pain or emerge as a consequence of growing up with chronic pain. These vulnerabilities can have long-reaching effects well beyond childhood, contributing to adult chronic pain, other health impairments, substance use, and social and emotional impairments. If progress is to be made in reducing the impact of pain and disability through the lifespan, greater efforts need to be directed toward understanding why, for whom, and how pain occurring in childhood affects subsequent adult pain and health using developmental lifespan approaches. Many childhood vulnerabilities (e.g., sleep disturbances) are modifiable with psychological interventions, which can play a key role in reducing risk for maladaptive adult outcomes. A priority is to further develop and test early targeted interventions in childhood to reduce childhood chronic pain as well as build resiliency to promote positive adult outcomes. A future research agenda is delineated including the need for longitudinal cohort studies from childhood into adulthood, and testing of both targeted early intervention to reduce risk and build resiliency to enhance long-term adult pain, health, developmental, and social outcomes.
Sincerely, Andrew Rice, Scientific Program Chair
#IASP2021 • #IASPWorldCongress • #IASPVirtualEducation
The Greatest Teacher, Failure is: Falsely Positive, Falsely Negative, And Falsely Interpreted Clinical Trials Of Pain Treatments ROBERT DWORKIN, PHD University of Rochester School of Medicine and Dentistry, United States The John D. Loeser Distinguished Award Lecture is presented to a person who creates a tradition that instructs, inspires, and challenges clinicians and researchers to understand human pain, and the suffering it produces, in the broadest ways possible. The 2021 recipient is Robert Dworkin, PhD, United States. Dr. Dworkin, PhD received his BA from the University of Pennsylvania and his PhD from Harvard University. He is Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry and Professor in the Center for Health + Technology at the University of Rochester in New York, USA. Dr. Dworkin is also Director of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration, and an Associate Editor of PAIN and a member of the Editorial Boards of Canadian Journal of Pain and Journal of Pain. His research interests involve the development of improved treatment and preventive interventions for neuropathic and musculoskeletal pain and the identification of factors that increase the assay sensitivity and informativeness of clinical trials of pain treatments. He has authored over 300 journal articles, which have been cited over 45,000 times.
WHAT INSPIRED YOU TO PURSUE A CAREER IN PAIN RESEARCH? I have a PhD in research psychology. Originally, I was doing research on personality and psychopathology. I was always drawn to using biological approaches in my work, but that initial research eventually led me to look at coping behaviors. I was interested in how people cope with diagnoses – for multiple sclerosis, Huntington’s disease, and other conditions in which patients experience great uncertainty about the future. In doing that work, many people talked about their pain and how they coped with that. It became a bridge into pain research. I’ve been working in this area now for 40 years. AT WHAT POINT DID YOU START FOCUSING ON OPTIMIZING CLINICAL TRIALS? I started thinking about clinical trials 25, maybe 30 years ago. At that time, it became clear to many of us that we didn’t necessarily understand why we were getting some of the negative results we were getting in trials. We’d do a clinical trial of a drug or other treatment that we had a very good reason to believe would be better at relieving pain than placebo, and it just didn’t work out that way. Sometimes you’re pretty confident that it’s a false negative. If you have a lot of early trials that show efficacy, but then you do the larger confirmatory trial and the treatment doesn’t do any better than the placebo, it’s important to understand why. Bob Rappaport, a neurologist at the Food and Drug Administration [FDA], and others were interested in understanding for these trials: Was it really a negative trial of a drug that truly lacks efficacy? Or is something else going on? Not only was this a source of consternation for pharmaceutical companies who were spending a lot of money to conduct these trials, but it was also a big issue for academic researchers like me and the regulatory agencies. What do you make of these negative results? What can we learn from them? That was the beginnings of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) project – and that was the origin of my interest, and certainly the FDA’s interest, in setting up various kinds of partnerships
#IASP2021 • #IASPWorldCongress • #IASPVirtualEducation
Wednesday 9 June
Wednesday 9 June
DAILY NEWS DAILY NEWS
iaspvirtualcongress.evareg.com
to optimize the design of clinical trials. The objective of the whole process, by conducting more informative and efficient clinical trials, is to improve the efficacy and safety of treatments for pain. WHAT ARE SOME OF THE BIGGEST CHALLENGES IN CONDUCTING AN INFORMATIVE CLINICAL TRIAL? It seems to be getting harder and harder to show separation from the placebo – or when you can show separation, the effect is much smaller than one might like. This is true not only for pain medications but for psychiatric drugs, too. It’s even true for drugs that we know are effective and have been approved by the FDA or the European regulatory agency, the European Medicines Agency [EMA]. Everyone has their own hypothesis of why this is the case, but no one really knows the reason. My own feeling is that at least part of the explanation is that clinical trials are being done differently than they were 25 years ago. When I started doing trials for chronic pain in the 1990s, a lot of the trials were done at academic medical centers. Today, more and
more are being done at dedicated clinical research operations, which often recruit potential participants from the community rather than from clinical practice. Such individuals either may have milder pain, or might have failed to respond to all the treatments they’ve tried. In the 1990s, to do a trial to test a treatment for fibromyalgia, we put an advertisement in the local Sunday paper. By Monday morning, we had 200 phone calls from people interested in participating. But the last trial I did of fibromyalgia – we didn’t even think about advertising in the paper. You’d only get five or six phone calls, and most patients wouldn’t be eligible for the trial, for one reason or another. Importantly, we have efficacious treatments that we didn’t have back then. There are three drugs approved in the US for fibromyalgia, for example. Patients are prescribed those, and if they do well enough on them they would not be inclined to participate in a trial. That leads to a smaller reservoir of potential participants, which can make it harder to get these trials done. Today, we also see a greater response in the placebo groups in clinical trials, and, possibly, in the active medication groups, too. It may be that the public is better informed about these new drugs and clinical trials. They have a sense of optimism about advances in medicine. So when a person does enroll in a clinical trial, even though they may know there is only a 50/50 chance they will receive the active drug, that optimism, their expectations, and perhaps the attention they get from the study staff come together to contribute to them feeling better over the course of three months – the typical length of chronic pain clinical trials. That can make it harder to get the separation you need from placebo in the trial. HOW DID YOU ORIGINALLY GET INVOLVED WITH ACTTION? IMMPACT, which started in 2002, was a smaller, less formal organization. Bob Rappaport had the idea of putting out a grant application for a larger, more formal FDA-sponsored public-private partnership to help improve clinical trials. About a dozen years ago, my colleague and close
#IASP2021 • #IASPWorldCongress • #IASPVirtualEducation
friend Dennis Turk at the University of Washington and I, along with others who were involved with the case, but no one really knows the reason. My own feeling is that at least part of the explanation is that clinical trials are being done differently than they were 25 years ago. When I started doing trials for chronic pain in the 1990s, a lot of the trials were done at academic medical centers. Today, more and more are being done at dedicated clinical research operations, which often recruit potential participants from the community rather than from clinical practice. Such individuals either may have milder pain, or might have failed to respond to all the treatments they’ve tried. In the 1990s, to do a trial to test a treatment for fibromyalgia, we put an advertisement in the
local Sunday paper. By Monday morning, we had 200 phone calls from people interested in participating. But the last trial I did of fibromyalgia – we didn’t even think about advertising in the paper. You’d only get five or six phone calls, and most patients wouldn’t be eligible for the trial, for one reason or another. Importantly, we have efficacious treatments that we didn’t have back then. There are three drugs approved in the US for fibromyalgia, for example. Patients are prescribed those, and if they do well enough on them they would not be inclined to participate in a trial. That leads to a smaller reservoir of potential participants, which can make it harder to get these trials done.
Wednesday 9 June
Wednesday 9 June
DAILY NEWS DAILY NEWS
iaspvirtualcongress.evareg.com
Today, we also see a greater response in the placebo groups in clinical trials, and, possibly, in the active medication groups, too. It may be that the public is better informed about these new drugs and clinical trials. They have a sense of optimism about advances in medicine. So when a person does enroll in a clinical trial, even though they may know there is only a 50/50 chance they will receive the active drug, that optimism, their expectations, and perhaps the attention they get from the study staff come together to contribute to them feeling better over the course of three months – the typical length of chronic pain clinical trials. That can make it harder to get the separation you need from placebo in the trial.
HOW DID YOU ORIGINALLY GET INVOLVED WITH ACTTION? IMMPACT, which started in 2002, was a smaller, less formal organization. Bob Rappaport had the idea of putting out a grant application for a larger, more formal FDA-sponsored publicprivate partnership to help improve clinical trials. About a dozen years ago, my colleague and close friend Dennis Turk at the University of Washington and I, along with others who were involved with IMMPACT, applied for this initial grant for ACTTION. We received the grant, which started in 2011, and the work has been incredibly gratifying ever since.
CAN YOU DESCRIBE SOME OF THE IMPROVEMENTS IN CLINICAL TRIALS THAT ACTTION HAS HELPED TO FOSTER?
make a difference in whether a trial of a truly efficacious treatment could give us a negative result.
One way of thinking about what we try and do is provide an evidence base for clinical trials of treatments for acute pain and chronic pain. Dennis and I want whatever we do to be relevant to trials of all types of pain treatments, and, more generally, to clinical research about pain and its causes and consequences. So we try to make general recommendations for how to do clinical trials better, in a more evidence-based way.
Trials also rely on the standard zero to 10 pain scale to measure pain, but most of the time we don’t do much else to help patients figure out which number represents what they feel. The question was raised about whether we should train patients when they do their pain ratings so that they do them more thoughtfully and consistently. We developed a pretty intense training program, so instead of a patient just quickly dashing off a number in the chaos between dinner and bedtime, they are encouraged to go off by themselves and really think about the number that represents the pain they feel so we can have a more accurate pain rating.
We’ve devoted a lot of effort to coming up with diagnostic criteria for the major acute and chronic pain conditions to help investigators figure out how you define the condition you are studying. You can’t just say, ‘We’re doing a clinical trial for a treatment for low back pain’ and then take anyone who says they have low back pain. We need a more standardized and systematic way to diagnose low back pain to determine who should be eligible for the trial. Another major effort has involved analyzing published trials from the FDA database to look at factors that may influence the separation we see between drug and placebo. The idea is that if you can identify something that makes it harder to show an effective drug is truly effective, then you want to consider that in designing your trial. For example, most drug trials will have participants fill out a daily diary of their pain a week or so before the trial and we see that, with some people, those numbers bounce all over the place. It turns out, if you remove patients who have these excessively variable baseline pain ratings in various chronic pain conditions, your separation between drug and placebo increases. We aren’t sure why this is, but this can
WHAT ADVANCES IN PAIN CLINICAL TRIALS DO YOU HOPE TO SEE IN THE NEXT FIVE TO 10 YEARS? I think we can do better than the zero to 10 scale in trials; it’s been around for decades. There’s got to be a way to make it easier for patients to tell us how much pain they have and how it is affecting them.
#IASP2021 • #IASPWorldCongress • #IASPVirtualEducation
Wednesday 9 June
IASP 2022 WORLD CONGRESS ON PAIN
iaspvirtualcongress.evareg.com
Toronto, Canada • 19–23 September 2022 Much of the work we’ve done has looked at how to show benefit when a drug is effective, but we also need to think more about safety, risk, and tolerability. It doesn’t matter for the patients how good a drug is in reducing headache, for example, if it makes us so sleepy that we can’t work. In the future, we want to think about more comprehensive outcome measures so we can not only say that this drug is effective for pain, but that it’s safe and patients can tolerate it well. ACTTION is going to devote more time to that kind of benefit-risk calculus. Another thing we are thinking about is precision medicine and personalized pain treatments. How can we identify which patients are more likely to respond to physical therapy? To a drug? To acupuncture? We are devoting quite a bit of our attention to those questions because they are so important and timely. But this also taps into the benefit-risk analysis. That is because we don’t just want to know that this person will get relief from this drug for their low back pain; we want that person to respond without debilitating side effects or an increased risk of serious adverse events like heart attack. We need to take into account, as we pursue research
into personalized pain treatments, not just the benefits of these interventions but also the potential risks. Finally, also in terms of maximizing overall benefit while potentially avoiding treatment risks, we’d like to focus on prevention of chronic pain; we don’t know enough about it. Why does one individual who throws out their back while playing tennis develop a chronic condition while another person with the same kind of injury gets better in a few weeks? Once we can identify who is at most risk for chronic pain, we could potentially intervene and prevent the problem from ever occurring in the first place. It might be a drug, physical therapy, or a psychological treatment. This preventive piece is going to be an incredibly important focus in the future – I think just as important as precision medicine itself. HOW DO YOU FEEL ABOUT WINNING THE JOHN D. LOESER DISTINGUISHED LECTURE AWARD? It’s a huge honor – I’m thrilled and delighted. I can think of no one in the pain community who better exemplifies the critical importance of a truly biopsychosocial perspective in understanding and treating pain than Dr. Loeser, and it has been very gratifying to be able to collaborate with him. But this work really is a team effort and an international effort. Over the years, Dennis and I have worked with dozens and dozens of people who have contributed to all these efforts, both back when we were focusing on IMMPACT and now with ACTTION. This award really should be shared by all the people who have collaborated with us over all these years.
Submit a Proposal
Refresher Course • Hands-On Workshop IASP World Congress on Pain will return to an in-person meeting in 2022 with a virtual hybrid offering. Help shape the education around pain research and submit a proposal to provide attendees with the latest information, knowledge, and to discover the latest in pain science.
#IASP2021 • #IASPWorldCongress • #IASPVirtualEducation
Wednesday 9 June
DAILY NEWS DAILY NEWS
Thank You To Our Supporters
SILVER
GOLD
BRONZE
PLATINUM
IASP ACKNOWLEDGES AND THANKS THE FOLLOWING COMPANIES AND ORGANIZATIONS FOR THEIR SUPPORT.
Exhibitors Alan Edwards Centre for Research on Pain (McGill University) Anatomic
Helixmith Medoc Pain Medicine News
Desert Harvest
Pfizer
GlaxoSmithKline Consumer Healthcare
Tilray Wolters Kluwer
#IASP2021 • #IASPWorldCongress • #IASPVirtualEducation